Progeria

Overview

Hutchinson–Gilford progeria syndrome (HGPS), usually called Progeria, is an ultra-rare genetic condition in which a disease-causing change in the LMNA gene leads to production of progerin, an abnormal lamin A protein that damages cells and tissues. It begins in childhood and causes severe, progressive premature aging, especially accelerated disease of the heart and blood vessels; untreated disease has historically resulted in death at about 14 years of age on average. Base editing in HGPS mice (pubmed.ncbi.nlm.nih.gov)

The current disease-specific standard of care is lonafarnib (Zokinvy), an oral farnesyltransferase inhibitor that reduces the risk of death but does not correct the underlying LMNA mutation or constitute a cure. The FDA approved it on November 20, 2020, for eligible patients with HGPS aged 12 months and older. In the evidence supporting approval, lonafarnib-treated patients had an estimated 2.5-year survival advantage versus matched untreated patients over follow-up of up to 11 years. FDA orphan-drug approval record FDA approval summary (accessdata.fda.gov)

Scope of Recent Research (2020–present)

Since 2020, Progeria research has become more mechanistically targeted: investigators are pursuing permanent correction of the causal DNA variant with base editing, reduction of toxic progerin RNA with antisense medicines, and drugs or peptides that interrupt harmful progerin interactions. The field has produced unusually strong proof-of-concept results in cell and mouse models, but direct genetic correction has not yet entered a human Progeria trial; therefore, a curative therapy remains preclinical rather than clinically established. In vivo base editing study Antisense-oligonucleotide screening Progerinin Phase 2a trial record (pubmed.ncbi.nlm.nih.gov)

Major Breakthroughs and Emerging Therapies

Gene editing is the clearest potential route to a one-time cure. In a landmark 2021 study, an adenine base editor—a CRISPR-derived tool that changes a single DNA letter without cutting both DNA strands—corrected 87% to 91% of the disease allele in patient-derived fibroblasts. In a mouse model carrying the human HGPS mutation, one AAV9 viral-vector dose corrected the mutation in roughly 20% to 60% of cells across examined organs at six months, reduced progerin, improved vascular pathology, and extended median lifespan from 215 to 510 days. In vivo base editing rescues HGPS in mice (pubmed.ncbi.nlm.nih.gov)

A separate preclinical program tested transient, non-integrating delivery of an adenine base editor, aiming to avoid prolonged editor production. It corrected the LMNA mutation in patient cells, reduced progerin RNA and protein, and improved skin features in mice. This work is important because it highlights a possible path toward limiting exposure to the editing machinery, although unwanted nearby “bystander” edits were still detected in some edited cell lines. Transient adenine-base-editor expression (pmc.ncbi.nlm.nih.gov)

RNA therapies seek to prevent progerin from being made. Antisense oligonucleotides are short, chemically modified nucleic acids designed to bind RNA. A 2021 systematic screen of 198 candidates identified molecules that interfere with the abnormal LMNA splicing event that produces progerin; the optimized lead reduced progerin RNA in vivo and extended lifespan in a Progeria mouse model. A related peptide-linked antisense approach also reduced progerin in several tissues, including the aorta, and modestly extended mouse lifespan. Systematic antisense-oligonucleotide screening Targeted antisense therapy (pubmed.ncbi.nlm.nih.gov)

Small molecules and protein-interaction therapies offer nearer-term combinations with lonafarnib. Progerinin (SLC-D011) was designed to interfere with progerin–lamin A binding; in mouse models it improved disease-related findings and lengthened lifespan, which led to the current human dose-finding trial. Another 2023 preclinical strategy used a peptide to block progerin’s interaction with BUBR1, a protein involved in chromosome segregation during cell division; it improved cellular disease features and extended lifespan in Progeria mice. Neither approach has yet demonstrated clinical efficacy or a cure in people. Progerinin preclinical study Progerin C-terminal peptide study (pubmed.ncbi.nlm.nih.gov)

Clinical Trials and Experimental Approaches

The principal active interventional trial listed as of August 8, 2026 is NCT06775041, a Phase 2a randomized, open-label study of progerinin sponsored by PRG Science & Technology Co., Ltd. at Boston Children’s Hospital. The trial began on January 13, 2025, enrolled 10 participants, and tests daily progerinin doses of 500 to 1,500 mg alongside lonafarnib, which the protocol treats as standard of care. The registry was last updated February 9, 2026, listed the study as active but not recruiting, and reported no results; its estimated March 2026 completion date had passed without posted outcomes by August 8, 2026. NCT06775041 trial record (clinicaltrials.gov)

Lonafarnib remains the only approved disease-specific therapy. Its approval rested on two open-label studies compared with a well-matched untreated natural-history cohort, rather than on a conventional randomized placebo-controlled trial—a practical consequence of the disease’s extreme rarity. FDA approval summary (pubmed.ncbi.nlm.nih.gov)

Methodologies and Scientific Approaches

Researchers combine patient-derived cells with genetically engineered mouse models that reproduce the common human LMNA c.1824C>T mutation. Gene-editing studies measure correction of the DNA variant, restoration of normal RNA splicing, progerin reduction, nuclear shape, vascular smooth-muscle preservation, fibrosis, function, and survival. Delivery platforms include AAV9 vectors and transient non-integrating viral systems for base editors, while RNA programs compare antisense sequence targets, chemical backbones, and tissue delivery. In vivo base editing rescues HGPS in mice Transient adenine-base-editor expression Antisense-oligonucleotide screening (pubmed.ncbi.nlm.nih.gov)

Biomarker development is also improving trial readiness. A 2023 plasma-progerin immunoassay distinguished untreated people with HGPS from non-HGPS participants and found that lonafarnib-associated reductions in circulating progerin correlated with better survival, making plasma progerin a promising pharmacodynamic marker—an indicator that a treatment is affecting its intended biological target. Plasma progerin immunoassay (pubmed.ncbi.nlm.nih.gov)

Leading Institutions and Funding

Major contributors include the Broad Institute of MIT and Harvard, Harvard University, the National Human Genome Research Institute at NIH, Vanderbilt University Medical Center, Baylor College of Medicine, Boston Children’s Hospital, and the Progeria Research Foundation (PRF); these institutions were central to the landmark base-editing study. Boston Children’s Hospital is also the site of the current progerinin trial, with PRG Science & Technology as sponsor. In vivo base editing rescues HGPS in mice NCT06775041 trial record (pubmed.ncbi.nlm.nih.gov)

PRF is a key translational funder and organizer: it reports funding more than $9.1 million across 85 Progeria-related grants since its founding, while its current typical research awards are one to two years at about $75,000 per year. Its stated priorities include candidate therapies, gene- and cell-based approaches, and natural-history research that can supply clinical-trial outcome measures. PRF grants funded PRF research-funding opportunities (progeriaresearch.org)

Strengths, Limitations, and Challenges

The strongest feature of the field is that the predominant HGPS mutation is a single, well-defined DNA change, making direct correction technically plausible. Base editing has already produced large benefits in relevant mouse models, and RNA approaches can lower production of the toxic protein without permanently altering DNA. However, the crucial challenge is delivering sufficient treatment safely and durably to the arteries, heart, bone, skin, and other affected tissues in children. In vivo base editing rescues HGPS in mice Targeted antisense therapy (pubmed.ncbi.nlm.nih.gov)

Important safety and translation questions remain. Base editors can create unintended edits at nearby bases, and their long-term safety, tissue coverage, immune effects, and ability to treat established vascular disease require human evidence. RNA medicines avoid permanent DNA alteration but may need repeat dosing, and preclinical work shows that decreases in progerin RNA do not always translate equally into decreases in the longer-lived progerin protein across tissues. Lonafarnib extends survival but is not mutation-correcting, and its human evidence necessarily relies on small cohorts and external untreated comparators. Transient adenine-base-editor expression Antisense-oligonucleotide screening FDA approval summary (pmc.ncbi.nlm.nih.gov)

Outlook and Future Directions

A cure for Progeria is biologically conceivable but not yet close enough to describe as imminent: the most compelling curative strategy, in vivo base editing of LMNA, has so far succeeded only in preclinical models. Near-term milestones to watch are publication of the Phase 2a progerinin results; confirmation that plasma progerin can serve as a reliable response marker; improved whole-body delivery of transient or tissue-targeted editors; and formal human safety studies of an LMNA-correcting gene-editing therapy. The available evidence supports cautious optimism, not a claim that a human cure has already been achieved. NCT06775041 trial record Plasma progerin immunoassay In vivo base editing rescues HGPS in mice (clinicaltrials.gov)

References

• In vivo base editing rescues Hutchinson-Gilford progeria syndrome in mice — Koblan et al., Nature, 2021.
• FDA orphan-drug approval record for Zokinvy (lonafarnib) — U.S. Food and Drug Administration, 2020.
• FDA approval summary for lonafarnib — U.S. Food and Drug Administration authors, Clinical Therapeutics, 2022.
• Systematic screening identifies therapeutic antisense oligonucleotides for HGPS — Puttaraju et al., Nature Medicine, 2021.
• A targeted antisense therapeutic approach for HGPS — Erdos et al., Nature Medicine, 2021.
• Transient expression of an adenine base editor corrects the HGPS mutation — Wagner et al., Communications Biology, 2022.
• Progerinin ameliorates premature-senescence phenotypes of HGPS — Kang et al., Communications Biology, 2021.
• Unique progerin C-terminal peptide ameliorates HGPS phenotype by rescuing BUBR1 — Zhang et al., Nature Aging, 2023.
• Progerinin Phase 2a trial: NCT06775041 — ClinicalTrials.gov, 2026.
• Plasma progerin immunoassay and clinical evaluation — Gordon et al., Circulation, 2023.
• PRF grants funded — The Progeria Research Foundation, 2024.
• PRF research-funding opportunities — The Progeria Research Foundation, 2026.